002644.SZ
Lanzhou Foci Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 8.18
−0.24%Aug 19, 2026, 11:06 UTC
The indirect controlling shareholder of Foci Pharmaceutical changed to Gansu Pharmaceutical Group during the reporting period, while the controlling shareholder remained unchanged.
Source:Aug 19, 2026, 11:06 UTC
Foci Pharmaceutical announced its 2026 first-half results with revenue of 440 million yuan, up 2.55% year-on-year, and net profit attributable to shareholders of 39.74 million yuan, up 32.00%.
Source:Aug 19, 2026, 11:06 UTC
Foci Pharmaceutical proposed a cash dividend of 0.6 yuan per 10 shares (tax included) to all shareholders based on 511 million shares, with no bonus shares or capital reserve conversion.
Source: